(Reuters) – Novo Nordisk, the world’s top maker of diabetes drugs, is investing 115 million pounds ($145 million) in a new research center in Britain, undeterred by Brexit. The Danish company said on Monday it would invest the money over 10 years in the center based at the University of Oxford, which will employ 100 […]
Research & Development
Microscopic submarines release drugs depending on acid concentration
Researchers have developed tiny ‘submarines’ that speed through the stomach using gastric acid for fuel. The proton-driven micromotors have a pH-sensitive polymer coating that can be loaded with drugs and released in the stomach. Gastric acid can be destructive for orally-administered, pH-sensitive pharmaceuticals, including antibiotics. Although some coatings can protect substances from gastric acid, they […]
Scientists develop nanoparticles to ‘suffocate’ tumor cells
A team of researchers from the Shanghai Institute of Ceramics, Chinese Academy of Sciences and the East China Normal University have developed polyvinyl pyrrolidone modified nanoparticles that serve as a deoxygenation agent against tumor cells. The therapy, which is described in Nature Nanotechnology, targeted cancer cells by cutting off the tumor’s blood supply to deprive and ‘suffocate’ […]
MIT, Brigham researchers deliver strands of RNA using ultrasound
Researchers from the Massachusetts Institute of Technology and Brigham & Women’s Hospital have developed a technique to deliver strands of RNA to colon cells using bursts of ultrasound waves. The team’s technique turned down the production of a protein involved in inflammatory bowel disease in mice. The paper, which was published in Gastroenterology, described a simple […]
Study finds financial ties between researchers, industry associated with positive trial results
A study conducted by a team of U.S. researchers found that financial ties between researchers and the companies that make the drugs they are studying are independently associated with positive trial results. The team’s work was published in The BMJ this week. The study was observational, so the results can’t be used to draw concrete conclusions. But the […]
Researchers develop responsive, insulin-releasing skin patch
Researchers from the University of North Carolina at Chapel Hill, North Carolina State University and Changchun Institute of Applied Chemistry at the Chinese Academy of Sciences have developed a skin patch that measures blood glucose levels and releases insulin when levels climb too high. The team’s work testing the patch in mice was published earlier this month […]
leon-nanodrugs, Bionpharma to develop microjet reactor-based dermatological product
leon-nanodrugs GmbH and Bionpharma Inc. said yesterday that the 2 groups inked a deal to develop a dermatological product using leon-nanodrugs’ microjet reactor nanotechnology platform. The companies will share the development of the undisclosed product. Development will be done at leon-nanodrugs’ U.S.-based formulation partner CoreRx in Clearwater, Florida. Bionpharma will market and distribute the product […]
Orthocell, J&J’s DePuy Synthes ink R&D deal for stem cell treatment
Orthocell (ASX:OCC) said today that it landed a research collaboration deal with Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes for its Ortho-ATI stem cell regenerative therapy. The 2 groups are planning a collaborative study for the 1st quarter in 2017, led by Allan Wang from the University of Western Australia. In previous studies, Ortho-ATI has proven […]
Study shows Alzheimer’s drug activates stem cells in teeth
Researchers from King’s College London have shown that an Alzheimer’s drug can stimulate the stem cells found in tooth pulp and generate a protective material, dentine, in large cavities. The team’s work was published yesterday in Scientific Reports. If the soft pulp of a tooth becomes infected after a traumatic event, a thin layer of dentine is […]
Intarcia, Calibr collaborate to develop peptide therapeutic for Medici pump
Intarcia Therapeutics and the California Institute for Biomedical Research said today that the 2 groups will collaborate to develop a peptide therapeutic for patients with type II diabetes and obesity. The drug will be derived from Calibr’s stapled-peptide technology platform, combined with Intarcia’s late stage investigational GLP-1 therapy and delivered using the match-sized Medici osmotic […]
